Biotechnology
Skyhawk Therapeutics Announces Final Fifteen-Month Results from Phase 1/2 Clinical Trial of SKY-0515 in Huntington's Disease Patients
* The fifteen-month dataset represents the final analysis from the Phase 1/2 study * At the Month 15 primary timepoint, SKY-0515-treated patients showed a +1.59-point difference in Composite Unified Huntington's Disease Rating Scale (cUHDRS) change from baseline versus overlap-weighted extern...
Minesto presents today at Aktiedagen i Stockholm
GOTHENBURG, Sweden, Sept. 16, 2026 /PRNewswire/ -- Minesto's CEO Dr Martin
Edlund presents today at Aktiedagen i Stockholm by Aktiespararna, 15 September
2026
The event is livestreamed, and Minesto will be presenting at 18.30 CEST:
Aktiespararna
CordenPharma Appoints Dr. Jean-Luc Herbeaux as Chief Executive Officer to Lead Next Phase of Growth
* Dr. Jean-Luc Herbeaux appointed Chief Executive Officer of CordenPharma, effective 1 October 2026 * Dr. Michael Quirmbach to transition from President & CEO to Board Member and Senior Advisor, remaining actively involved with CordenPharma * Planned leadership transition builds on 12 ye...
Ractigen Therapeutics to Present First-in-Human RNA Activation Data in Duchenne Muscular Dystrophy as a Late-Breaking Oral Presentation at the 31st Annual Congress of the World Muscle Society
* Late-Breaking selection at the 31st Annual World Muscle Society Congress — a designation reserved for findings the program committee determines to be of immediate importance to the field * Presentation expected to provide the first clinical evidence that a small activating RNA (saRNA) can u...
Xylo Bio Achieves Clinical-Stage Milestone with XYL-1001, a Highly Selective Neuroplastogen Targeting Major Depressive Disorder
BOSTON, Sept. 15, 2026 /PRNewswire/ -- Xylo Bio, a clinical-stage biotechnology company developing novel neurotherapeutics for psychiatric and neurological disorders, today announced the first participants dosed in its Phase 1 clinical study of XYL-1001, a novel, selective 5-HT2A agonist being de...
Oral Presentation: Ivonescimab Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC: Positive Overall Survival Results from HARMONi-2 at WCLC 2026
HONG KONG, Sept. 15, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) today announced the presentation of positive overall survival (OS) results from the randomized, double-blind, multicenter, registrational Phase III HARMONi-2 study (AK112-303) at the 2026 World Conference on Lung Cancer (WCLC), organ...
5th Hong Kong International Biotechnology Conference and Exhibition (BIOHK2026) Officially Opens
HONG KONG, Sept. 11, 2026 /PRNewswire/ -- Hong Kong International Biotechnology Conference and Exhibition (BIOHK2026) officially opened on September 9, 2026, at the Hong Kong Convention and Exhibition Centre. Marking a key 5-year milestone, this flagship life sciences event connects Hong Kong, Ma...
REJURAN® COSMETICS Brings K-Beauty to LAFC Korean Heritage Night as Proud Skincare Partner
Korea's original PDRN brand connected with Los Angeles football fans through product sampling and creator experiences LOS ANGELES, Sept. 14, 2026 /PRNewswire/ -- REJURAN® COSMETICS, Korea's original PDRN brand from PharmaResearch, joined LAFC's Korean Heritage Night on Wednesday, Sept. 9, as a P...
Yuyu Pharma Expands Solar Power at Manufacturing Facility, Bringing On-Site Capacity to 1 MW
New solar installation expected to supply more than 30% of the factory's electricity needs and pay for itself in approximately three years SEOUL, South Korea, Sept. 14, 2026 /PRNewswire/ -- Yuyu Pharma (KRX: 000220) has completed a major expansion of solar power at its manufacturing facility in ...
NEXTBIOMEDICAL Marks Its Largest-Ever Presence at CIRSE 2026 with Exhibition Booth and Learning Center, Highlighting Global Clinical Evidence
SEOUL, South Korea, Sept. 14, 2026 /PRNewswire/ -- NEXTBIOMEDICAL, a medical device company specializing in innovative therapeutic solutions, participated in CIRSE 2026, the annual congress of the Cardiovascular and Interventional Radiological Society of Europe, held in Copenhagen, Denmark, from ...
Altruist Biologics Congratulates Partner LongBio Pharma on the BLA Acceptance of LP-003 by the China NMPA
* Enabled by Altruist's integrated CMC development platform, GMP manufacturing and regulatory service capabilities, LP-003 has successfully advanced from concept to potential commercialization. * LP-003 is the first innovative drug independently developed by LongBio Pharma to advance to BLA s...
Waters Sets Benchmark for Standardized Spectral Flow Cytometry with Commercial Launch of BD FACSDiscover A7 Cell Analyzer
* Enables routine 50+ parameter experiments with BD SpectralFX™ Technology, accelerating breakthrough discoveries in the fight against cancer and other diseases. * Minimizes instrument and user differences with first-of-its-kind FACSTruQ™ Technology, achieving industry-leading standardization...
Results from Phase III Study of Trastuzumab Botidotin versus T-DM1 in HER2-Positive Breast Cancer Published in JCO
CHENGDU, China, Sept. 14, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or "the Company", 6990.HK) announced thatresults from the phase III registrational study of its novel human epidermal growth factor receptor 2 (HER2)-targeted antibody–drug conjugate...
Tomonari Abe, President of Abe Yoando Pharma, Selected as First Japanese Speaker at Longevity Investors Conference 2026 in Switzerland
- Head of 295-year-old Japanese Pharmaceutical Pioneer to Present Asia's Longevity Growth Strategies and Bioscientific Research Initiatives at Prestigious Conference - TOKYO and GSTAAD, Switzerland, Sept. 14, 2026 /PRNewswire/ -- Abe Yoando Pharma Co., Ltd., a nearly 300-year-old pharmaceutical ...
Antengene Publishes Preclinical Research Paper on CD73 Small Molecule Inhibitor ATG-037 Combined with Selinexor in Cancer Gene Therapy
SHANGHAI and HONG KONG, Sept. 14, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune ...
Accro Bioscience Announces Inclusion of AC-101 tablets in the NMPA CDE's "Caring Plan-Extension" Pilot Program for Rare Disease Drug Development
NEW YORK and SUZHOU, China, Sept. 13, 2026 /PRNewswire/ -- On September 14, 2026 (China Standard Time, UTC+8), Accro Bioscience announced that AC-101 tablets have been included in the Rare Diseases Innovative Drug Development Encouragement Pilot Program (the "Caring Plan-Extension", known in Chin...
FDA Approves Telix's Brain Cancer Imaging Drug Pixclara
* Pixclara® is the first FDA-approved FET-PET imaging drug for glioma (brain cancer). * Approval addresses a significant unmet need, helping physicians to differentiate recurrent or progressive glioma from treatment-related change in adults and pediatric patients. * FET-PET imaging is recom...
Ivonescimab Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC: Positive Overall Survival Results from HARMONi-2 Presented at WCLC 2026
HONG KONG, Sept. 13, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) today announced the presentation of positive overall survival (OS) results from the randomized, double-blind, multicenter, registrational Phase III HARMONi-2 study (AK112-303) at the 2026 World Conference on Lung Cancer (WCLC), organ...
Agenda for the 4th Hong Kong Clinical-driven Robotics and Embodied AI Technology (CREATE) Symposium Officially Released
Leading Experts from Medicine, Research, Industry and Investment Revealed HONG KONG, Sept. 11, 2026 /PRNewswire/ -- Scheduled for September 22–23, 2026, the 4th Hong Kong Clinical-driven Robotics and Embodied AI Technology (CREATE) Symposium will be held at the Charles K. Kao Auditorium in Hong ...
2026 World Laureates Foundation Prize Unveiled in Shanghai
11 WLF Prize laureates; the first time scientists of Chinese descent have been awarded; inaugural WLF Prize for Young Scientists launched. SHANGHAI, Sept. 11, 2026 /PRNewswire/ -- A news report from Yicai Global: On the morning of September 10, the winners of the 2026 World Laureates Foundation ...
Week's Top Stories
Most Reposted
Agoda Begins Limited Public Beta of New AI Assistant That Turns Travel Ideas into Bookable Trips
[Picked up by 286 media titles]
2026-09-15 11:00Futurise Impact Report 2025 Highlights Progress in Regulatory Innovation Future-Ready Technologies
[Picked up by 272 media titles]
2026-09-09 13:26Novo Holdings invests in ForYou Medical to support global growth in advanced wound care manufacturing
[Picked up by 264 media titles]
2026-09-10 15:00New ASEAN Study Reveals Businesses Are Rethinking Hiring and Investment as Growth Priorities Shift
[Picked up by 260 media titles]
2026-09-10 07:45AKSADRON Releases Impact Report 2025, Showcasing the Growth of Malaysia's Drone Sports Talent Ecosystem
[Picked up by 255 media titles]
2026-09-14 15:36